The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response.
 
Gopa Iyer
No Relationships to Disclose
 
Francois Audenet
No Relationships to Disclose
 
Sumit Middha
No Relationships to Disclose
 
Maria Isabel Carlo
No Relationships to Disclose
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Samuel Funt
Stock and Other Ownership Interests - Kite, a Gilead company
 
Hikmat Al-Ahmadie
No Relationships to Disclose
 
David B. Solit
Honoraria - Loxo; Pfizer
Consulting or Advisory Role - Loxo; Pfizer
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; UpToDate
Consulting or Advisory Role - Agensys; AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Lilly; Merck; Oncogenex; Roche/Genentech; Sanofi; Seagen
Research Funding - Agensys (Inst); Genentech (Inst); Genentech/Roche (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech